On January 26th, Aoxiang Pharmaceutical announced that the company plans to use its own funds and/or self raised funds to repurchase some of its issued RMB ordinary shares (A-shares) through centralized bidding trading on the Shanghai Stock Exchange trading system. The repurchase amount of shares shall not be less than RMB 50 million (inclusive) and not exceed RMB 100 million (inclusive). The repurchase price of shares shall not exceed RMB 14 per share (inclusive). The purpose of repurchasing shares is intended for implementing the company’s equity incentive and/or employee stock ownership plan.
Scan code to share